Studies using in vitro cell experiments and MM NOD/SCID mouse models showed that γ-secretase inhibitors (GSI, LY3039478) dose-dependently prevent BCMA cleavage, increasing BCMA surface expression levels on MM cells. Here, TNFRSF17 is linked to Miyoshi myopathy.